Helius Medical (HSDT) Form 4 HELIUS MEDICAL / Joyce N LaViscount ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

LaViscount Joyce N

(Last) (First) (Middle)

C/O HELIUS MEDICAL TECHNOLOGIES, INC.

642 NEWTOWN YARDLEY ROAD, SUITE 100

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HELIUS MEDICAL TECHNOLOGIES, INC. [ HSDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CFO and COO

3. Date of Earliest Transaction (Month/Day/Year)
12/07/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$12.52	12/07/2019		D(1)			20,000	(2)	03/16/2020	Class A Common Stock	20,000	$0.00	0	D
Employee Stock Option (Right to Buy)	$12.52	12/07/2019		A(1)		20,000		(2)	03/16/2025	Class A Common Stock	20,000	$0.00	20,000	D
Employee Stock Option (Right to Buy)	$3.2	12/07/2019		D(3)			150,000	(2)	10/21/2020	Class A Common Stock	150,000	$0.00	0	D
Employee Stock Option (Right to Buy)	$3.2	12/07/2019		A(3)		150,000		(2)	10/21/2025	Class A Common Stock	150,000	$0.00	150,000	D
Employee Stock Option (Right to Buy)	$5.35	12/07/2019		D(4)			120,000	(2)	07/13/2020	Class A Common Stock	120,000	$0.00	0	D
Employee Stock Option (Right to Buy)	$5.35	12/07/2019		A(4)		120,000		(2)	07/13/2026	Class A Common Stock	120,000	$0.00	120,000	D

Explanation of Responses:

1. These two reported transactions involved an amendment of an outstanding option originally granted on March 16, 2015 resulting in the deemed cancellation of the March 16, 2015 option and the grant of a replacement option with the same terms other than the expiration date.

2. Immediately exercisable.

3. These two reported transactions involved an amendment of an outstanding option originally granted on October 21, 2015 resulting in the deemed cancellation of the October 21, 2015 option and the grant of a replacement option with the same terms other than the expiration date.

4. These two reported transactions involved an amendment of an outstanding option originally granted on July 13, 2016 resulting in the deemed cancellation of the July 13, 2016 option and the grant of a replacement option with the same terms other than the expiration date.

Remarks:

Effective January 22, 2018, the Issuer effected a 1-for-5 reverse stock split of the Issuer's Class A Common Stock. All share numbers herein give effect to the reverse stock split. In addition, all conversion or exercise prices of derivative securities in column 2 of Table II herein are translated into U.S. Dollars from Canadian dollars.

	/s/ Joyce LaViscount	12/16/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.